2022-05-09 22:20:05来源：医脉通阅读：12次
编辑：Uni
医脉通整理，未经授权请勿转载
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月3日-6月7日召开。医脉通特梳理了转移性
全体大会
01
摘要号：LBA3
随机III期DESTINY-Breast04研究：T-DXd对比医生选择的治疗方案用于HER2低表达的不可切除和/或转移性乳腺癌患者的疗效
标题：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
报告人：Shanu Modi, MD
单位：Memorial Sloan Kettering Cancer Center
口头报告
01
摘要号：1000
随机III期DESTINY-Breast03研究：T-DXd对比T-DM1治疗HER2阳性的不可切除和/或转移性乳腺癌患者的的安全性随访
标题：Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
报告人：Erika P. Hamilton, MD
单位：Sarah Cannon Research Institute/Tennessee Oncology
02
摘要号：LBA1001
随机III期TROPiCS-02研究：sacituzumab govitecan（SG）对比医生选择的治疗方案用于激素受体阳性/HER2阴性晚期乳腺癌患者的疗效
标题：Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
报告人：Hope S. Rugo, MD, FASCO
单位：Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center
03
摘要号：1002
Patritumab deruxtecan，HER3靶向抗体偶联药物，治疗HER3表达的转移性乳腺癌患者的I/II期研究结果
标题：Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
报告人：Ian E. Krop, MD, PhD
单位：Dana-Farber Cancer Institute
04
摘要号：LBA1003
PALOMA-2研究：
标题：Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
报告人：Richard S. Finn, MD
单位：David Geffen School of Medicine at UCLA
05
摘要号：LBA1004
随机II期MAINTAIN研究：抗
标题：A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
报告人：Kevin Kalinsky, MD, MS
单位：Winship Cancer Institute, Emory University
06
摘要号：1005
FAKTION研究：芳香化酶抑制剂治疗复发或进展后，氟维司群联合capivasertib对比氟维司群联合安慰剂治疗ER阳性转移性乳腺癌患者的增强生物标志物分析的总生存和更新的无进展生存数据
标题：Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.
报告人：Robert Hugh Jones, PhD, FRCP
单位：Velindre Cancer Centre and School of Medicine Cardiff University
07
摘要号：1006
SOLAR-1研究：Alpelisib联合氟维司群治疗HR阳性、HER2阴性晚期乳腺癌患者的NGS生物标志物分析
标题：Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
报告人：Dejan Juric, MD
单位：Massachusetts General Hospital Cancer Center, Harvard Medical School
08
摘要号：1007
IIR/III期NRG-BR002研究：新发低转移性乳腺癌患者行标准系统治疗联合或不联合立体定向全身放疗（SBRT）和/或手术切除（SR）（NCT02364557）
标题：NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).
报告人：Steven J. Chmura, MD, PhD
单位：The University of Chicago Medicine
09
摘要号：1008
2000-2017年筛查、早期治疗和转移治疗对降低美国女性不同分子亚型乳腺癌死亡率的贡献
标题：Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.
报告人：Jennifer Lee Caswell-Jin, MD, BA
单位：Stanford University
壁报讨论
01
摘要号：1018
海报：396
BYLieve 研究：Alpelisib联合内分泌治疗对HR阳性、HER2阴性、PIK3CA突变的晚期乳腺癌患者的基线生物标志物分析和CDK4/6抑制剂治疗持续时间决定的无进展生存期
标题：Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
报告人：Dejan Juric, MD
单位：Massachusetts General Hospital Cancer Center, Harvard Medical School
02
摘要号：1022
海报：400
开放标签II期研究：拉索昔芬联合
标题：Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
报告人：Senthil Damodaran, MD, PhD
单位：The University of Texas MD Anderson Cancer Center
03
摘要号：1023
海报：401
IB/II期研究：BET抑制剂ZEN-3694联合talazoparib治疗无gBRCA1/2突变的TNBC患者的1b/2期研究
标题：A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
报告人：Philippe Georges Aftimos, MD
单位：Institut Jules Bordet, Université Libre de Bruxelles
04
摘要号：1024
海报：402
II期plasmaMATCH研究队列E：
标题：Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).
报告人：Alistair E. Ring, MD, MRCP, MA
单位：The Royal Marsden NHS Foundation Trust
壁报展示
01
摘要号：535
海报：307
绝经后激素受体阳性乳腺癌初始5年辅助内分泌治疗的有效性和安全性：一项系统综述和网络荟萃分析
标题：Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.
报告人：Hao Liao
单位：北京大学肿瘤医院
02
摘要号：539
海报：311
卵巢功能抑制在40岁以上的早期乳腺癌患者中并不是必不可少的
标题：Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.
报告人：Jianqiao Xian, MD
单位：中山大学肿瘤防治中心
03
摘要号：582
海报：353
外周脂质组学分析与集成机器学习预测乳腺癌新辅助治疗的反应
标题：Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.
报告人：王佳妮
单位：中国医学科学院北京协和医学院
04
摘要号：588
海报：359
多中心、单臂、前瞻性II期MUKDEN 01研究初步分析：
标题：Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
报告人：牛楠
单位：中国医科大学附属盛京医院
05
摘要号：TPS618
海报：383b
前瞻性、单臂、开放标签的III期研究：
标题：Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
报告人：罗静
单位：四川省医学科学院·四川省人民医院
06
摘要号：TPS620
海报：384b
单臂II期PILHLE-001研究：吡咯替尼联合表柔比星和
标题：Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.
报告人：Yuan Xia
单位：中山大学孙逸仙纪念医院
备注：排名不分先后，按照摘要号进行
如有遗漏或任何问题，请给我们留言~
参考来源：https://meetings.asco.org/meetings/2022-asco-annual-meeting